科研动态PubMed 摘要

使用钾结合剂对慢性肾脏病合并射血分数降低的心力衰竭患者进行快速肾素-血管紧张素-醛固酮系统抑制剂优化:一项随机、双盲、安慰剂对照试验。

PubMed 白名单日捞 · 2026-10-14

完整摘要 · 中文译文

肾素-血管紧张素-醛固酮抑制剂(RAASi)改善射血分数降低的心力衰竭(HFrEF)患者的结局,但其使用常因慢性肾脏病(CKD)患者的高钾血症而受限。这项双盲、安慰剂对照、随机试验评估了环硅酸锆钠(SZC)是否能使合并CKD 3-5期且血清钾为5.0-5.5 mmol/L的HFrEF患者在14周内实现RAASi上调滴定。主要二分类结局定义为在14周内或otherwise未达到高钾血症(血清钾≥5.6 mmol/L)的情况下达到RAAS抑制治疗的目标剂量。参与者(n = 112)按1:1随机接受环硅酸锆钠(SZC)或安慰剂。符合方案(PP)分析包括SZC组53例中的43例(81%)和安慰剂组59例中的53例(90%);意向性治疗(ITT)分析包括全部112例。试验结束时,SZC组43例参与者中有24例(56%)在未发生高钾血症的情况下达到目标RAASi剂量,而安慰剂组53例患者中有15例(28%)达到该目标(PP分析,p = 0.006;ITT分析,p = 0.007)。在ITT分析中,SZC组参与者达到目标剂量且未达到钾5.6 mmol/L的可能性是安慰剂组的3倍(OR = 3.16;95% CI 1.35-7.39;p = 0.008)。两组之间未观察到不良事件方面的显著差异。SZC似乎可安全支持合并CKD的HFrEF患者快速优化RAASi。本试验由AstraZeneca通过Externally Sponsor资助。 ed 科学研究基金 ESR-19-20174。试验注册:Clinicaltrials.gov NCT05004363 和 EudraCT 编号 2020-002946-18。

完整摘要 · 英文原文

Renin-angiotensin-aldosterone inhibitors (RAASi) improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF), but their use is often limited by hyperkalaemia in chronic kidney disease (CKD) patients. This double-blind, placebo-controlled, randomised trial evaluated whether sodium zirconium cyclosilicate (SZC) enables RAASi up-titration in HFrEF patients with CKD stages 3-5 and serum potassium of 5.0-5.5 mmol/L over 14 weeks. The primary binary outcome was defined as achieving the target dose of RAAS inhibition therapy without reaching hyperkalaemia (serum potassium ≥5.6 mmol/L) over 14 weeks or otherwise. Participants (n = 112) were randomised 1:1 to receive sodium zirconium cyclosilicate (SZC) or placebo. The per-protocol (PP) analyses included 43 out of 53 (81%) in the SZC arm and 53 out of 59 participants (90%) in the placebo arm; the intention-to-treat (ITT) analyses included all 112. At the end of the trial, 24 of 43 participants (56%) in the SZC group achieved the target RAASi dose without developing hyperkalaemia compared with 15 of 53 patients (28%) in the placebo group (PP analysis, p = 0.006, ITT analysis, p = 0.007,). Participants in the SZC group were 3 times more likely to reach the target dose without reaching potassium 5.6 mmol/L (OR = 3.16; 95% CI 1.35-7.39; p = 0.008) than in the placebo group (ITT analysis). No significant differences in adverse events between the two groups were observed. SZC appears to safely support rapid RAASi optimisation in HFrEF patients with CKD. This trial was funded by AstraZeneca via Externally Sponsored Scientific Research grant ESR-19-20174. Trial Registration: Clinicaltrials.gov NCT05004363 and EudraCT number 2020-002946-18.

English
Rapid Renin Angiotensin Aldosterone System inhibitor optimisation in patients with chronic kidney disease and heart failure with reduced ejection fraction using potassium binder: a randomised, double-blinded, placebo-controlled trial.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界